These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 32773771)

  • 1. A cost-effectiveness analysis of genomic sequencing in a prospective versus historical cohort of complex pediatric patients.
    Yeung A; Tan NB; Tan TY; Stark Z; Brown N; Hunter MF; Delatycki M; Stutterd C; Savarirayan R; Mcgillivray G; Stapleton R; Kumble S; Downie L; Regan M; Lunke S; Chong B; Phelan D; Brett GR; Jarmolowicz A; Prawer Y; Valente G; Smagarinsky Y; Martyn M; McEwan C; Goranitis I; Gaff C; White SM
    Genet Med; 2020 Dec; 22(12):1986-1993. PubMed ID: 32773771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of exome and genome sequencing for children with rare and undiagnosed conditions.
    Lavelle TA; Feng X; Keisler M; Cohen JT; Neumann PJ; Prichard D; Schroeder BE; Salyakina D; Espinal PS; Weidner SB; Maron JL
    Genet Med; 2022 Jun; 24(6):1349-1361. PubMed ID: 35396982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does genomic sequencing early in the diagnostic trajectory make a difference? A follow-up study of clinical outcomes and cost-effectiveness.
    Stark Z; Schofield D; Martyn M; Rynehart L; Shrestha R; Alam K; Lunke S; Tan TY; Gaff CL; White SM
    Genet Med; 2019 Jan; 21(1):173-180. PubMed ID: 29765138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective comparison of the cost-effectiveness of clinical whole-exome sequencing with that of usual care overwhelmingly supports early use and reimbursement.
    Stark Z; Schofield D; Alam K; Wilson W; Mupfeki N; Macciocca I; Shrestha R; White SM; Gaff C
    Genet Med; 2017 Aug; 19(8):867-874. PubMed ID: 28125081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world diagnostic outcomes and cost-effectiveness of genome-wide sequencing for developmental and seizure disorders: Evidence from Canada.
    Regier DA; Loewen R; Chan B; Ehman M; Pollard S; Friedman JM; Stockler-Ipsiroglu S; van Karnebeek C; Race S; Elliott AM; Dragojlovic N; Lynd LD; Weymann D
    Genet Med; 2024 Apr; 26(4):101069. PubMed ID: 38205742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness frameworks for comparing genome and exome sequencing versus conventional diagnostic pathways: A scoping review and recommended methods.
    Ferket BS; Baldwin Z; Murali P; Pai A; Mittendorf KF; Russell HV; Chen F; Lynch FL; Lich KH; Hindorff LA; Savich R; Slavotinek A; Smith HS; Gelb BD; Veenstra DL
    Genet Med; 2022 Oct; 24(10):2014-2027. PubMed ID: 35833928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis of the diagnostic and clinical utility of exome and genome sequencing in pediatric and adult patients with rare diseases across diverse populations.
    Chung CCY; Hue SPY; Ng NYT; Doong PHL; ; Chu ATW; Chung BHY
    Genet Med; 2023 Sep; 25(9):100896. PubMed ID: 37191093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of genome sequencing for diagnosing patients with undiagnosed rare genetic diseases.
    Incerti D; Xu XM; Chou JW; Gonzaludo N; Belmont JW; Schroeder BE
    Genet Med; 2022 Jan; 24(1):109-118. PubMed ID: 34906478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluations of exome and genome sequencing in pediatric genetics: considerations towards a consensus strategy.
    Olde Keizer RACM; Henneman L; Ploos van Amstel JK; Vissers LELM; Frederix GWJ
    J Med Econ; 2021 Nov; 24(sup1):60-70. PubMed ID: 34915793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meeting the challenges of implementing rapid genomic testing in acute pediatric care.
    Stark Z; Lunke S; Brett GR; Tan NB; Stapleton R; Kumble S; Yeung A; Phelan DG; Chong B; Fanjul-Fernandez M; Marum JE; Hunter M; Jarmolowicz A; Prawer Y; Riseley JR; Regan M; Elliott J; Martyn M; Best S; Tan TY; Gaff CL; White SM;
    Genet Med; 2018 Dec; 20(12):1554-1563. PubMed ID: 29543227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of Targeted Exome Analysis as a Diagnostic Test in Glomerular Diseases.
    Jayasinghe K; Wu Y; Stark Z; Kerr PG; Mallett AJ; Gaff C; Martyn M; Goranitis I; Quinlan C
    Kidney Int Rep; 2021 Nov; 6(11):2850-2861. PubMed ID: 34805637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic sequencing for the diagnosis of childhood mitochondrial disorders: a health economic evaluation.
    Wu Y; Balasubramaniam S; Rius R; Thorburn DR; Christodoulou J; Goranitis I
    Eur J Hum Genet; 2022 May; 30(5):577-586. PubMed ID: 34099885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular diagnostic yield of genome sequencing versus targeted gene panel testing in racially and ethnically diverse pediatric patients.
    Abul-Husn NS; Marathe PN; Kelly NR; Bonini KE; Sebastin M; Odgis JA; Abhyankar A; Brown K; Di Biase M; Gallagher KM; Guha S; Ioele N; Okur V; Ramos MA; Rodriguez JE; Rehman AU; Thomas-Wilson A; Edelmann L; Zinberg RE; Diaz GA; Greally JM; Jobanputra V; Suckiel SA; Horowitz CR; Wasserstein MP; Kenny EE; Gelb BD
    Genet Med; 2023 Sep; 25(9):100880. PubMed ID: 37158195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost and diagnostic yield of exome sequencing for children with suspected genetic disorders: a benchmarking study.
    Dragojlovic N; Elliott AM; Adam S; van Karnebeek C; Lehman A; Mwenifumbo JC; Nelson TN; du Souich C; Friedman JM; Lynd LD
    Genet Med; 2018 Sep; 20(9):1013-1021. PubMed ID: 29300375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world economic evaluation of prospective rapid whole-genome sequencing compared to a matched retrospective cohort of critically ill pediatric patients in the United States.
    Diaby V; Babcock A; Huang Y; Moussa RK; Espinal PS; Janvier M; Soler D; Gupta A; Jayakar P; Diaz-Barbosa M; Totapally B; Sasaki J; Jayakar A; Salyakina D
    Pharmacogenomics J; 2022 Jul; 22(4):223-229. PubMed ID: 35436997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trio genome sequencing for developmental delay and pediatric heart conditions: A comparative microcost analysis.
    Jegathisawaran J; Tsiplova K; Hayeems RZ; Marshall CR; Stavropoulos DJ; Pereira SL; Thiruvahindrapuram B; Liston E; Reuter MS; Manshaei R; Cohn I; Jobling R; Kim RH; Mital S; Ungar WJ
    Genet Med; 2022 May; 24(5):1027-1036. PubMed ID: 35219592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review of the assessment of the clinical utility of genomic sequencing: Implications of the lack of standard definitions and measures of clinical utility.
    Azuelos C; Marquis MA; Laberge AM
    Eur J Med Genet; 2024 Apr; 68():104925. PubMed ID: 38432472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating the costs of genomic sequencing in cancer control.
    Gordon LG; White NM; Elliott TM; Nones K; Beckhouse AG; Rodriguez-Acevedo AJ; Webb PM; Lee XJ; Graves N; Schofield DJ
    BMC Health Serv Res; 2020 Jun; 20(1):492. PubMed ID: 32493298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective evaluation of whole-exome sequencing as a first-tier molecular test in infants with suspected monogenic disorders.
    Stark Z; Tan TY; Chong B; Brett GR; Yap P; Walsh M; Yeung A; Peters H; Mordaunt D; Cowie S; Amor DJ; Savarirayan R; McGillivray G; Downie L; Ekert PG; Theda C; James PA; Yaplito-Lee J; Ryan MM; Leventer RJ; Creed E; Macciocca I; Bell KM; Oshlack A; Sadedin S; Georgeson P; Anderson C; Thorne N; Melbourne Genomics Health Alliance ; Gaff C; White SM
    Genet Med; 2016 Nov; 18(11):1090-1096. PubMed ID: 26938784
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.